PreclinicalEvaluation of [68Ga]Ga-CS03as a Novel GPC3-Targeted Probe for Imaging GPC3 in HepatocellularCarcinoma Models

MOLECULAR PHARMACEUTICS · Published 2026-08-04 · Available online 3 Aug 2026 · DOI 10.1021/acs.molpharmaceut.6c00559

Authors (8)

Dai Shi, Wujian Mao, Yutao Xie, Pan Zhou, Minqiang Hu, Qingyu Lin, Yuxia Liu, Dengfeng Cheng

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Shi, D., Mao, W., Xie, Y., et al. (2026). PreclinicalEvaluation of [68Ga]Ga-CS03as a Novel GPC3-Targeted Probe for Imaging GPC3 in HepatocellularCarcinoma Models. MOLECULAR PHARMACEUTICS. https://doi.org/10.1021/acs.molpharmaceut.6c00559

Related articles

• A CosmeticProduct Containing PEG Derivatives InducesAnti-PEG IgM Mainly through Stimulation of the Spleen Cells in Mice · MOLECULAR PHARMACEUTICS · 2026 · Same journal
• [68Ga]Ga-DOTA-DP-UBI 29-41: A Novel 68Ga-LabeledUbiquicidin 29-41 Derivative Containing d -Prolinefor Bacterial Infection PET Imaging · MOLECULAR PHARMACEUTICS · 2026 · Same journal
• PreclinicalEvaluation of 177Lu-LabeledAnti-CLDN18.2 VHH-Fc for Radioimmunotherapy in Gastric Cancer · MOLECULAR PHARMACEUTICS · 2026 · Same journal
• Development of [111In]In-CHX-A″-DTPA-αCD68for ImmunoSPECT to Image Murine Macrophages · MOLECULAR PHARMACEUTICS · 2026 · Same journal
• Design, Synthesis, and Preclinical Evaluation of Novel Dimeric RM2-Based Radioligands for GRPR-Targeted Breast Cancer Imaging · MOLECULAR PHARMACEUTICS · 2026 · Same journal
• IntegratingTumor Targeting and Half-Life Extensioninto a Dual-Surfaced Single-Domain ADAPT Protein · MOLECULAR PHARMACEUTICS · 2026 · Same journal
• Tuningthe Structural Properties of a Single-DomainAntibody Scaffold for Improved Fibroblast Activation Protein Targeting · MOLECULAR PHARMACEUTICS · 2026 · Same journal
• AutomatedRadiosynthesis of High-Molar-Activity 4-Borono-2-[18F]Fluorophenylalanine: Validation in Rodent Tumor Modelsand Nonhuman Primates · MOLECULAR PHARMACEUTICS · 2026 · Same journal
• Evaluationof 161Tb-Labeled DOTA-Ibandronatefor Targeted Radionuclide Therapy in Bone Metastases · MOLECULAR PHARMACEUTICS · 2026 · Same journal
• Predicting pHmax and Salt DisproportionationRisk for Basic Drugs · MOLECULAR PHARMACEUTICS · 2026 · Same journal